Abstract:Introduction: The chemoresistance mechanism of diffuse large B-cell lymphoma (DLBCL) is still poorly understood, and patient prognosis remains unsatisfactory. This study aimed to investigate drug resistance mechanisms in non-germinal center B-cell-like (non-GCB) DLBCL. Methods: Doxorubicin (DOX)-resistant OCI-Ly3 cells were generated through long-term incubation of cells in a medium with gradually increasing DOX concentrations. The expression levels of genes related to drug metabolism were determined using a functional gene grouping polymerase chain reaction (PCR) array. Drug-resistant proteins were identified using bioinformatics, and molecular association networks were subsequently generated. The association and mechanism of key genes were determined using a dual-luciferase reporter assay System and chromatin immunoprecipitation (ChIP). The expression of drug-resistant genes and target genes was then measured using Western blotting and immunohistochemistry. The correlation between gene expressions was analyzed using Spearman’s rank correlation coefficient. Results: Using the PCR array, MDR1 was identified as the key gene that regulates DOX resistance in OCI-Ly3/DOX-A100, a non-GCB DLBCL cell line. The dual-luciferase reporter assay system demonstrated that MDR1 transcription could be inhibited by PRDM1. ChIP results showed that PRDM1 had the ability to bind to the promoter region (−1,132 to −996) of MDR1. In OCI-Ly3/DOX cells, NF-κB activity and PRDM1 expression decreased with an increase in drug-resistant index, whereas MDR1 expression increased with enhanced drug resistance. Immunohistochemical analysis revealed that relative MDR1 expression was higher than that of PRDM1 in human DLBCL tissue samples. A negative correlation was observed between MDR1 and PRDM1. Conclusion: In non-GCB DLBCL cells, NF-κB downregulates PRDM1 and thereby promotes MDR1 transcription by terminating PRDM1-induced transcriptional inhibition of MDR1. Such a mechanism may explain the reason for disease recurrence in non-GCB DLBCL after R-CHOP or combined CHOP with bortezomib treatment. Our findings may provide a potential therapeutic strategy for reducing drug resistance in patients with DLBCL.

Zinc Ribbon Domain-Containing 1 (znrd1) Mediates Multidrug Resistance of Leukemia Cells Through Regulation of P-Glycoprotein and Bcl-2

Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer]

Zinc ribbon domain containing 1 protein: modulator of multidrug resistance, tumorigenesis and cell cycle.

Zinc as a potential regulator of the BCR-ABL oncogene in chronic myelocytic leukemia cells

Antimultidrug-Resistant Effect and Mechanism of A Novel Ca-4 Analogue Mz3 on Leukemia Cells

Increased 14-3-3 Zeta Expression In The Multidrug-Resistant Leukemia Cell Line Hl-60/Vcr As Compared To The Parental Line Mediates Cell Growth And Apoptosis In Part Through Modification Of Gene Expression

Reversal of Multidrug Resistance by Magnetic Fe3o4 Nanoparticle Copolymerizating Daunorubicin and Mdr1 Shrna Expression Vector in Leukemia Cells

Disruption of Dntp Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade

The Interaction Between PDCD4 and YB1 is Critical for Cervical Cancer Stemness and Cisplatin Resistance.

Knocking Down Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) Reverts Chemoresistance through Inactivation of Src and Bcr-Abl Proteins

Dysregulated MDR1 by PRDM1/Blimp1 is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

LRPPRC Contributes to the Cisplatin Resistance of Lung Cancer Cells by Regulating MDR1 Expression

Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling

Deactivation of Signal Transducer and Activator of Transcription 3 Reverses Chemotherapeutics Resistance of Leukemia Cells Via Down-Regulating P-Gp

Ribosome Biogenesis Regulator 1 Homolog (RRS1) Promotes Cisplatin Resistance by Regulating AEG-1 Abundance in Breast Cancer Cells

[Nf-Kappab Regulating Expression of Mdr1 Gene and P-gp to Reverse Drug-Resistance in Leukemic Cells].

[Inhibitory Effect of 14-3-3ζ on the Proliferation of HL-60 Cells and HL-60/VCR Cells].

Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line

Overcoming ABCB1-mediated Multidrug Resistance by Transcription Factor BHLHE40

PML-RARα Stabilized by Zinc in Human Acute Promyelocytic Leukemia NB4 Cells

Involvement of Annexin A1 in Multidrug Resistance of K562/ADR Cells Identified by the Proteomic Study